Peer Review History
| Original SubmissionJuly 14, 2025 |
|---|
|
Dear Dr. Wang, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ACADEMIC EDITOR: Please submit your revised manuscript by Oct 25 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Mohamed Hassany Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2.Thank you for stating the following financial disclosure: [This study was jointly supported by: the National Key Specialty of Traditional Chinese Medicine (Spleen and Stomach Diseases, 0500004), the Innovation Project of China Academy of Chinese Medical Sciences (CI2021A01001), and the Youth Science Foundation Project of the National Natural Science Foundation of China (82205104, 82104850)]. Please state what role the funders took in the study. If the funders had no role, please state: ""The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."" If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf. 3. We note that your Data Availability Statement is currently as follows: [All relevant data are within the manuscript and its Supporting Information files.] Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition). For example, authors should submit the following data: - The values behind the means, standard deviations and other measures reported; - The values used to build graphs; - The points extracted from images for analysis. Authors do not need to submit their entire data set if only a portion of the data was used in the reported study. If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories. If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access. 4. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? Reviewer #1: Yes Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Reviewer #1: This paper addresses an important and clinically relevant question: the determinants of symptom severity in concomitant epigastric pain syndrome (EPS) and non-erosive reflux disease (NERD) patients. It is derived from a large multicenter cohort of the Chinese tertiary centers, utilizes valid symptom and psychosocial instruments, and uses proper statistical modeling. The findings affirm the biopsychosocial model of gut–brain interaction disorders and emphasize that somatic symptom burden, sleep disturbance, and psychological distress are core factors related to the severity of symptoms in this overlap syndrome. The research is timely, clinically pertinent, and potentially can inform more integrated and multidisciplinary approaches in gastroenterology. With some clarifications and tweaks, the manuscript can be a helpful addition to the literature. Key Comments 1. Causality and Terminology: Because the design is cross-sectional, language regarding "predictors" should be qualified to highlight association, rather than causation. Clinical interpretation relies on this. 2. Novelty and Context: The study partially validates known associations between psychosocial variables and symptom load in functional GI disorders. Authors need to clearly indicate what is new about their findings in the NERD–EPS overlap group compared with previous GERD or dyspepsia groups. 3. Generalizability Sample is only from Chinese tertiary TCM hospitals, which may be a generalizability limitation for other healthcare institutions. Short description of cultural and healthcare system factors' influence on symptom reporting and overlap prevalence would be appreciated. 4. Clinical Implications Discussion would more effectively translate findings into practice. The suggestion to use PHQ-15 for screening is excellent and should be highlighted, as should the proposed stepwise biopsychosocial strategy for intervention. Direct guidance for gastroenterologists on how to integrate these measures into routine practice would be more effective. 5. Methodological Clarifications: Make sure all patients had endoscopy ruled out erosive disease and ulcers. Aspire to indicate whether Helicobacter pylori status was assessed. Determine if patients were being treated with PPIs or other proper meds upon evaluation. Precisely define "mixed labor" in the Methods section. Minor Comments Modernize nomenclature to add "disorders of gut–brain interaction (DGBI)" to include with FGID. Define EPS as a functional dyspepsia subtype in the first mention. Define unclear terms such as "psychosleep synergistic." Clarify the conclusion statement—streamline to highlight primary clinical drivers Utilize "urban professionals" or "high-stress urban employment" instead of "urban brain workers." Get statistical language more exact in terms of interaction tests. Round percentages and means to one decimal place if necessary. Double-check acronyms only defined in abstract and main body. Enhance grammar/spelling (e.g., spacing, Results section punctuation). Reviewer #2: • Thanks for inviting me to review this manuscript discusing Biopsychosocial predictors of symptom severity in Non-erosive Reflux Disease and Epigastric Pain Syndrome overlap: a multicenter cross-sectional study. It has a Large, multicenter sample and uses validated biopsychosocial questionnaires together with rigorous statistical modeling with diagnostics and a novel focus on NERD–EPS overlap, an under-researched subgroup. I have the following comments: 1- The conclusion in the abstract suggests causality (“predictors”), but as a cross-sectional study, only associations can be claimed. Wording should be more cautious (e.g., “associated with” rather than “predictors”). 2- The introduction could better position this study within global literature (most references are Asian cohorts). Limited discussion of underlying mechanisms and international prevalence. 3- In methods: - Recruitment strategy (hospital-based) may bias toward more symptomatic patients, limiting generalizability to community populations. - No justification for sample size or power calculation reported. - Overlap diagnosis depends heavily on questionnaires; objective tests (e.g., pH monitoring, gastric emptying) were not consistently applied. - Potential residual confounding (e.g., medication use, socioeconomic factors) not addressed. - All these should be discusses and mentioned in the limitations 4- In results: - Tables are dense; results could be more clinically interpretable (e.g., reporting odds of clinically meaningful symptom severity, not just β coefficients). - Some predictors (e.g., age, sex) were not significant in univariate but emerged in full model, this should be better explained. - No subgroup analysis (e.g., gender differences, severe vs. mild symptom groups), which could yield additional insights. 5- In discussion: - Over-interpretation in some parts (e.g., proposing specific treatments like SNRIs or CBT-SS without direct testing in this population). - Limited comparison with Western literature, generalizability to non-Chinese populations remains unclear. - “Protective effect” of mixed labor is interesting but underexplored — reverse causality cannot be excluded. ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
Dear Dr. Wang, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jan 08 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.
If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Mohamed Hassany Academic Editor PLOS ONE Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #1: Yes Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Reviewer #1: I would like to thank the authors for their careful and timely response to the reviewers’ and editor’s feedback. They have implemented all requested changes in the manuscript and have systematically addressed every comment, clarification, and suggestion. The revisions have clearly improved the structure, clarity, and overall scientific quality of the paper. At this stage, I am satisfied that all major and minor points have been adequately covered, and I have no further essential comments. I therefore consider the current version suitable for acceptance, pending any final formal or editorial checks required by the journal. Reviewer #2: Thank you for the opportunity to review this revised manuscript. The authors have conducted a commendable and much-needed study on the NERD-EPS overlap population, a clinically prevalent yet under-researched phenotype. Their thorough revisions have significantly strengthened the manuscript, addressing the majority of the previous reviewers' concerns with care and transparency. The manuscript is markedly improved and is now a strong, well-written paper. The authors have successfully reframed the language to emphasize association over causation, clarified the novelty of their findings within the global literature, and provided a more balanced discussion of limitations, particularly regarding generalizability. The addition of subgroup analyses and a clearer clinical interpretation of the regression coefficients are valuable enhancements. Remaining Suggestions: 1. While the authors have replaced "predictors" in most places, a subtle implication of prediction remains in the Results section (e.g., Page 33/75: "...emerged as statistically significant independent predictors..."). In a cross-sectional study, these are "correlates" or "independent factors associated with," not predictors. 2. The authors have scaled back from prescribing specific treatments (e.g., SNRIs, melatonin) to framing them as candidates for future research. This is appropriate. However, the clinical implications could be even more impactful by briefly suggesting how a gastroenterologist might act on a high PHQ-15 score today. A simple statement like, "A high PHQ-15 score should prompt consideration of a multidisciplinary referral to integrated psychiatry or health psychology services, where available, to address the central sensitization component," would provide direct and actionable guidance. 3. The results regarding sex are somewhat confusing and could be clarified for the reader. The multivariate model suggests female sex is associated with lower GSRS scores (a "protective effect"), yet the text on Page 80 states, "male patients... tended to have higher GSRS scores than female patients." A sentence acknowledging this contrast and hypothesizing why their cohort might differ (e.g., cultural help-seeking behaviors in men, specific to the overlap phenotype) would resolve this confusion for the reader. 4. The authors' reasoning for keeping two decimal places in percentages is valid from a data transparency standpoint. However, in the main text and abstract, it does impede readability (e.g., "66.67%"). A good compromise would be to report percentages to whole numbers in the abstract and main text for flow, while retaining the precise values in the supplementary data tables. Most readers will not derive different meaning from 66.67% versus 67%. This manuscript is eligible for publication. The remaining points are minor and pertain to fine-tuning language and interpretation rather than fundamental flaws in the study's design, analysis, or conclusions. The study makes a valuable contribution to the DGBI literature by highlighting the paramount role of somatic symptom burden in this overlap population, providing a clear rationale for integrating the PHQ-15 into routine clinical assessment. ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #2: Yes: Mohamed Alboraie ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. |
| Revision 2 |
|
Biopsychosocial factors associated with symptom severity in the overlap of non-erosive reflux disease and epigastric pain syndrome: a multicenter cross-sectional study PONE-D-25-38015R2 Dear Dr. Wang We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter, and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support . If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Mohamed Hassany Academic Editor PLOS ONE ********** |
| Formally Accepted |
|
PONE-D-25-38015R2 PLOS One Dear Dr. Wang, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Mohamed Hassany Academic Editor PLOS One |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .